Drug Trial Radar · NCT01437787
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Last checked: Nov 21, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
289
Actual
Start
Dec 31, 2011
Primary completion
Jun 30, 2014
Study completion Jun 30, 2014
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: * To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance imaging (MRI) (or computed tomography scan in patients with contraindications for MRI). Secondary Objectives: * To evaluate the effect on Myelofibrosis (MF)-associated symptoms (key MF symptoms) as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary. * To evaluate the Overall Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo. * To evaluate the Progression Free Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo. * To evaluate the durability of splenic response. * To evaluate the safety of IMP.
Conditions
- Hematopoietic Neoplasm
Interventions
SAR302503Drug
Pharmaceutical form:capsule Route of administration: oral
PlaceboDrug
Pharmaceutical form:capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response Rate (RR): Percentage of Participants Who Had a >=35% Reduction From Baseline in Volume of Spleen Size at The End Cycle 6Time frame: Baseline, Week 24
Locations
101 sites in 25 countries. Site status is shown where the registry gives one.
Investigational Site Number 840014
Scottsdale, Arizona
Investigational Site Number 840001
La Jolla, California
Investigational Site Number 840012
La Jolla, California
Investigational Site Number 840006
Los Angeles, California
Investigational Site Number 840013
Baton Rouge, Louisiana
Investigational Site Number 840008
Rochester, Minnesota
Investigational Site Number 840009
Newark, New Jersey
Investigational Site Number 840002
Canton, Ohio
Investigational Site Number 840004
Houston, Texas
Investigational Site Number 036001
Box Hill, Australia
Investigational Site Number 036005
Herston, Australia
Investigational Site Number 036003
Randwick, Australia
Investigational Site Number 036004
Tweed Heads, Australia
Investigational Site Number 036002
Wodonga, Australia
Investigational Site Number 040001
Vienna, Austria
Investigational Site Number 056003
Antwerp, Belgium
Investigational Site Number 056001
Leuven, Belgium
Investigational Site Number 076002
Jaú, Brazil
Investigational Site Number 076004
Porto Alegre, Brazil
Investigational Site Number 076001
Rio de Janeiro, Brazil
Investigational Site Number 124001
Montreal, Canada
Investigational Site Number 124003
Montreal, Canada
Investigational Site Number 124002
Saint John, Canada
Investigational Site Number 250006
Marseille, France
Investigational Site Number 250005
Nantes, France
Investigational Site Number 250004
Nîmes, France
Investigational Site Number 250002
Pierre-Bénite, France
Investigational Site Number 250007
Poitiers, France
Investigational Site Number 250003
Toulouse, France
Investigational Site Number 250001
Villejuif, France
Investigational Site Number 276006
Aachen, Germany
Investigational Site Number 276007
Bonn, Germany
Investigational Site Number 276008
Dresden, Germany
Investigational Site Number 276001
Mannheim, Germany
Investigational Site Number 348002
Budapest, Hungary
Investigational Site Number 348001
Debrecen, Hungary
Investigational Site Number 348007
Győr, Hungary
Investigational Site Number 348006
Kecskemét, Hungary
Investigational Site Number 348003
Miskolc, Hungary
Investigational Site Number 372002
Dublin, Ireland
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.